Fig. 5: The mechanism of cisplatin sensitization upon MAPKi-resistance acquisition in metastatic melanoma cells. | Cell Death & Disease

Fig. 5: The mechanism of cisplatin sensitization upon MAPKi-resistance acquisition in metastatic melanoma cells.

From: Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs

Fig. 5: The mechanism of cisplatin sensitization upon MAPKi-resistance acquisition in metastatic melanoma cells.The alternative text for this image may have been generated using AI.

The level of TAp73α negatively influences the sensitivity towards cisplatin and carboplatin treatment by regulation of NER in melanoma cells. A subset of MAPKi-resistant melanoma cells have a reduced level of TAp73α and are thereby sensitive to apoptosis induction mediated by platinum-based drug treatments

Back to article page